"The analyses of the CKD and low LDL-C subgroups were pre-specified, not post-hoc. CHF was pre-specified outcome. SGLT2 inhibitor subgroup is post-hoc I believe."

SGLT2 data is encouraging albeit way to small a sample size to place a "Gold Star" on it. Science is painstakingly slow and for good reason...it has to be "right" This class of pharmaceutiacals is likely going to change the approach to treating Type II Diabetes. If there truly is synergy, it will not go unnoticed. Patience Grasshopper...we mustn't lose sight. This is after all a brand new class of drug with an MOA that has no peers for comparision...I for one have set instant gratification aside. How could one not be encourged with this weekends presentations.